-
Impact of COVID-19 disease and vaccination on dermatological immune-mediated inflammatory diseases atopic dermatitis, psoriasis, and vitiligo: a Target2B! substudy
van Buchem-Post, N. F., Ouwerkerk, W., Stalman, E. W., van Dam, K. P. J., Wieske, L., Bekkenk, M. W., Wolkerstorfer, A., Spuls, P., Musters, A. H., Bosma, A. L., Hijnen, D.-J., Eftimov, F., Luiten, R. M. & T2B! immunity against SARS-CoV-2 study group, Apr 2025, In: Journal of dermatology. 52, 4, p. 624-633 10 p.Research output: Contribution to journal › Article* › Academic › peer-review
-
Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients
Boekel, L. & Wolbink, G. J., 1 Mar 2022, In: The Lancet Rheumatology. 4, 3, p. e154-e155Research output: Contribution to journal › Comment/Letter to the editor* › Academic
-
Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate?
T2B! immunity against SARS-CoV-2 study group, 1 Jan 2022, In: Multiple Sclerosis and Related Disorders. 57, p. 103416 5 p., 103416.Research output: Contribution to journal › Article* › Academic › peer-review
- All publications
